Singapore’s Merlion Seeks Further Licensing Deals After Bolster By U.S. FDA Fast-Track Status
This article was originally published in PharmAsia News
Executive Summary
Singapore’s MerLion Pharmaceuticals received a shot in the arm for its intravenous and oral antibiotic finafloxacin following U.S. FDA designation as a Qualified Infectious Disease Product and for fast track development. The designation opens up exclusive marketing rights for as long as 10 years if the candidate successfully completes Phase III trials.